Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial

BACKGROUND: Anti-angiogenic agents have been reported to exert promising clinical activity for advanced soft tissue sarcoma (STS). Apatinib, a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, is effective and safe for various solid tumors, but its role in STS remains unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Wenxi, Zhang, Hongmei, Chen, Jing, Zhang, Xing, Chen, Yong, Qu, Guofan, Huang, Gang, Zhou, Yuhong, Ye, Ting, Fan, Zhengfu, Yao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577792/
https://www.ncbi.nlm.nih.gov/pubmed/36267741
http://dx.doi.org/10.21037/atm-22-4229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577792/
https://www.ncbi.nlm.nih.gov/pubmed/36267741
http://dx.doi.org/10.21037/atm-22-4229

Ejemplares similares